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Abstract
Chronic Progressive External Ophthalmoplegia (CPEO) is characterized by ptosis and ophthalmoplegia and is usually caused by mitochondrial
DNA (mtDNA) deletions or mt-tRNA mutations. The aim of the present work was to clarify the genetic defect in a patient presenting with CPEO
and elucidate the underlying pathogenic mechanism. This 62-year-old female first developed ptosis of the right eye at the age of 12 and
subsequently the left eye at 45 years, and was found to have external ophthalmoplegia at the age of 55 years. Histopathological abnormalities were
detected in the patient’s muscle, including ragged-red fibres, a mosaic pattern of COX-deficient muscle fibres and combined deficiency of
respiratory chain complexes I and IV. Genetic investigation revealed the “common deletion” in the patient’s muscle and fibroblasts. Moreover, a
novel, heteroplasmic mt-tRNASer(UCN) variant (m.7486G>A) in the anticodon loop was detected in muscle homogenate (50%), fibroblasts (11%) and
blood (4%). Single-fibre analysis showed segregation with COX-deficient fibres for both genetic alterations. Assembly defects of mtDNA-encoded
complexes were demonstrated in fibroblasts. Functional analyses showed significant bioenergetic dysfunction, reduction in respiration rate and
ATP production and mitochondrial depolarization. Multilamellar bodies were detected by electron microscopy, suggesting disturbance in
autophagy. In conclusion, we report a CPEO patient with two possible genetic origins, both segregating with biochemical and histochemical defect.
The “common mtDNA deletion” is the most likely cause, yet the potential pathogenic effect of a novel mt-tRNASer(UCN) variant cannot be fully
excluded.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
Keywords: CPEO; mtDNA common deletion; mt-tRNA variant (m.7486G>A); Bioenergetic dysfunction; Translation defect
1. Introduction
One of the most common presentations of mitochondrial
DNA (mtDNA)-associated disease in adulthood is Chronic
Progressive External Ophthalmoplegia (CPEO), which is
characterized by progressive paralysis of the extraocular
muscles (EOMs) leading to ptosis and impaired eye movement
(ophthalmoplegia) [1].
CPEO is commonly caused by either primary mitochondrial
genetic defects such as single, large-scale mtDNA deletions
[1–6] and mt-tRNA point mutations [7–19], or multiple
mtDNA deletions, which are secondary to primary mutations in
nuclear genes responsible for the maintenance of mitochondrial
genome integrity [20,21]. The single 4,977 bp deletion, known
* Corresponding author. FMUC – Faculty of Medicine, University of
Coimbra, Coimbra, Portugal
E-mail address: mgrazina.fmuc@gmail.com (M. Grazina).
https://doi.org/10.1016/j.nmd.2017.11.006
0960-8966/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
ARTICLE IN PRESS
Please cite this article in press as: Mafalda Bacalhau, et al., Disclosing the functional changes of two genetic alterations in a patient with Chronic Progressive External Ophthalmoplegia:
Report of the novel mtDNA m.7486G>A variant, Neuromuscular Disorders (2017), doi: 10.1016/j.nmd.2017.11.006
Available online at www.sciencedirect.com
Neuromuscular Disorders ■■ (2017) ■■–■■
www.elsevier.com/locate/nmd
ScienceDirect
as the “common deletion”, is the most frequent genetic defect
found in patients with CPEO [22,23].
Muscle biopsies of CPEO patients typically comprise
subsarcolemmal accumulation of abnormal mitochondria
known as ragged-red fibres (RRF) and a mosaic pattern of
COX-deficient fibres showing abnormal COX activity.
Mitochondrial dysfunction occurs in a tissue where the number
of mutated mtDNA accumulates and exceeds a biochemical
threshold (threshold effect), which has been shown to vary for
different types of mutation, namely 50–80% for single, large-
scale mtDNA deletions and 70–95% for tRNA point mutations
[24,25]. Currently, more than half of disease-related mtDNA
point mutations have been reported within mt-tRNA genes that
cause defective translation and, consequently, combined
respiratory chain deficiency. Any deletion that eliminates an
mt-tRNA gene causes the same impairment of overall
mitochondrial-encoded proteins.
Studies reporting single, large-scale mtDNA deletions have
rarely provided functional evidences of the genetic defect
[3,5,26–31]; therefore, deeper investigation regarding the
affected cellular mechanisms is still needed.
The aim of the present work was to: (i) clarify the molecular
genetic defect and (ii) elucidate which cellular mechanisms are
affected in a patient presenting with CPEO that harbours a
novel mt-tRNASer(UCN) variant (m.7486G>A, ClinVar accession
number: SCV000492500) in addition to the “common
deletion”.
2. Patient and methods
2.1. Case report
The patient is a 62-year-old Portuguese Caucasian female
followed at the Neurology Department of the Coimbra Hospital
University Centre. The first clinical signs started at the age of
12 years old with slowly progressive ptosis of the right eyelid
and later involvement of the other eyelid at the age of 45 years
old. At this point, she was observed in the context of a corneal
ulcer and complaints that she had “difficulties keeping her eyes
open”. The disease maintained a slow progression and she was
diagnosed with CPEO at the age of 55 years old, with the
neurological examination revealing severe bilateral eyelid
ptosis, ophthalmoplegia and dysphonia. There was no reported
family history of CPEO or any other mitochondrial disorder.
Biological samples (peripheral blood, skin and muscle
biopsies) were collected from the patient investigated in the
present study during diagnostic investigation. There were no
samples available from maternal relatives.
The DNA samples of 200 adult healthy subjects of the same
ethnic background were used as controls.
Informed consent was obtained from the participants, as
recommended by the local Ethics Committee (CE-032/2014),
following the Tenets of the Helsinki Declaration.
2.2. Histology, histochemistry and quadruple
immunofluorescence in muscle
Routine histological (Haematoxylin & Eosin – H&E,
modified Gomori trichrome staining) and histochemical
(cytochrome c oxidase [COX], succinate dehydrogenase
[SDH], and sequential COX/SDH) analysis of the patient’s
skeletal muscle was performed, by following standard methods
[32].
Quadruple immunofluorescence was performed on
cryosectioned patient skeletal muscle (n = 1022) using
antibodies detecting subunits of OXPHOS complexes: anti-
NDUFB8 for Complex I (CI) and anti-COXI for Complex IV
(CIV), as described previously [33]. Mitochondrial mass was
quantified using an antibody to Porin and the myofibre
boundaries were labelled with the antibody to Laminin.
2.3. Skin derived cultured fibroblasts
Fibroblasts from skin biopsies of the patient and three
healthy Portuguese individuals (control group), without clinical
evidence of mitochondrial disease, were grown in complete
medium supplemented with 20% FBS (Gibco, Life
Technologies) and antibiotics.
2.4. Genetic investigation in different tissues
Total DNA was extracted from several tissues including
blood, dermal fibroblasts and muscle homogenate according to
standard protocols [34,35].
Individual COX-positive and COX-deficient muscle fibres
were isolated by laser microcapture, using a PALM Laser
Capture Microdissection system, and lysed to obtain total
cellular DNA, as previously described [36]. The stained
sections were then used for single-cell molecular analyses.
2.4.1. Whole mitochondrial genome sequencing
The presence of sequence variants and rearrangements were
detected by subjecting the patient’s mitochondrial genome to
next generation sequencing (NGS) in all available tissues,
enriched by a single amplicon long-range PCR followed by
massively parallel sequencing [37], using the HiSeq2000
platform (Illumina technology).
Haplogroup of patient was determined using the Haplogrep®
tool [38].
2.4.2. In silico analysis
The in silico analysis included the evolutionary conservation
of the MT-TS1 gene (mt-tRNASer(UCN)) from mtDNA of different
species, according to the proposed consensus panel [39] using
ClustalOmega|EBI® [40]. The location of the m.7486G>A
sequence variation in the cloverleaf structure of mt-tRNASer(UCN)
was verified from Mamit-tRNA® database [41].
2.4.3. Screening for mtDNA rearrangements
The presence of rearrangements in mtDNA was confirmed
in DNA derived from muscle homogenate, using an established
triplicate long range PCR approach for large-scale multiple and
single mtDNA deletions, amplifying approximately 10, 13 and
16 kb of the mtDNA in three separate reactions. For ~10 kb
amplification PCR forward-F (m.6122–6139) and reverse-R
(m.16133–16153) primers were used. For ~13 kb amplification
PCR F (m.13965–13984) and R (m.129-110) primers were used
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and for ~16 kb amplification PCR F (m.1157–1167) and R
(m.19-1) were employed. Cycling conditions were: 94 °C,
2 min; 35 cycles of 94 °C, 30 sec and 65 °C, 16 min; 72 °C
16 min. Amplifying PCR products were separated in 0.7%
agarose gels.
2.4.4. Single fibre studies
The m.7486G>A mt-tRNA mutation load was assessed by
pyrosequencing technology, in all available tissues and in
individual COX-positive and COX-deficient muscle fibres. The
PyroMark Assay Design Software v.2.0. (Qiagen) was used to
design locus-specific PCR and sequencing primers for the
m.7486G>A variant (biotinylated forward primer: m.7466–
7485; reverse primer: m.7583–7600; sequence primer:
m.7488–7502) and pyrosequencing was performed on the
Pyromark Q24 platform, according to the manufacturer’s
protocol. Pyromark Q24 software was used to quantify the
m.7486G>A heteroplasmy levels by directly comparing the
peak heights of both wild-type and mutant nucleotides at this
position [42].
The multiplex MTND1/MTND4 real-time PCR assay was
performed using DNA from individual COX-deficient and
COX-positive isolated muscle fibres and muscle homogenate
and the mtDNA deletion level was calculated from the
proportion of wild-type (MTND4) to total (MTND1) copy
number by the established ΔΔCt method [43]. PCR
amplification was completed in a 25 µl reaction in triplicate for
each sample, with each plate containing a serial dilution of
p7D1 plasmid for standard curve generation, as reported
previously [44].
2.5. Mitochondrial respiratory chain (MRC) enzymatic
activity and respiratory rate evaluation
Spectrophotometric determination of the catalytic activity of
the MRC complexes and segments was performed as previously
described [45].
Oxygen consumption rate (OCR) was measured in adherent
fibroblasts with a XF24 Extracellular Flux Analyser (Seahorse
Bioscience, Billerica, MA, USA), essentially as described by
Zhang and co-workers [46].
Each of the three controls’ and patient’s fibroblasts were
seeded in XF24 cell culture microplates (Seahorse Bioscience).
OCR was measured under basal conditions, and after
sequentially adding oligomycin, FCCP and rotenone plus
antimycin A were also added. Results were expressed as pmol
of O2 per minute per mg of protein, and allowed the evaluation
of the following bioenergetics parameters: basal respiration
(BR), maximum respiration (MR), spare respiratory capacity
(SRC), ATP production capacity (APC) and proton leak (PL).
All determinations were performed in 9–12 replicates for each
sample.
2.6. Analysis of mitochondrial membrane potential
Alterations in mitochondrial membrane potential (ΔΨm)
were determined using 1.5 µM of the cationic fluorescent probe
rhodamine 123 (Molecular probes, Invitrogen) in Krebs
medium, for 1 h, at 37 °C. Basal fluorescence (λ = 540 nm for
excitation and λ = 590 nm for emission) was measured using a
Microplate Spectrofluorometer Gemini EM (Molecular
Devices, USA) at 37 °C, for 5 min, followed by the addition of
2 µg/ml oligomycin and 2 µM FCCP. Results were expressed as
the difference between the basal fluorescence values and the
increase in rhodamine 123 fluorescence levels following
addition of oligomycin plus FCCP.
2.7. Relative quantification of MCR complexes
Samples were processed according to the protocol described
elsewhere [47]. Briefly, following supplementation of samples
with BN-sample buffer, the molecular weight marker
(NativeMARK Unstained Protein Standard, Life Technologies)
and 30 µg of samples were loaded into polyacrylamide gels and
run at 80V at 4 °C. The gel containing the proteins of interest
was eletrotransferred to a PVDF membrane (Hybond P 0.5 µm,
Amersham) for 2 h at 0.2A, at 4 °C. Afterwards, membranes
were incubated with monoclonal primary antibodies [anti-
NDUFA9 for CI; anti-SDHA for Complex II (CII); anti-
UQCRC2 for Complex III (CIII); anti-COX IV for CIV; and
anti-ATP5A for Complex V (CV)]. Membranes were incubated
with the anti-mouse HRP-conjugated secondary antibody
solution. Subsequently, detection was carried out using a
chemiluminescence substrate (Clarity Western ECL Substrate,
Bio-Rad), through the ChemiDocTM XRS+ System (Bio-Rad).
Protein band intensities were calculated by Quantity One® 1-D
software (Bio-Rad) from at least 3 independent experiments.
Relative semi-quantitation of each complex assembled was
performed in comparison to CII levels.
2.8. Transmission electron microscopy (TEM)
Muscle fibres from a fresh biopsy were fixed with 4%
glutaraldehyde in 0.2M sodium cacodylate buffer (pH 7.2) for
4 h. After rinsing twice in the same buffer, fibres were post-
fixed in 1% osmium tetroxide for 2 h. Following rinsing in
buffer, samples were then dehydrated in a graded ethanol series
(75–100%) before being embedded in Epoxy resin (Fluka
Analytical). Semi-thin sections (2 µm) were obtained and
stained with toluidine blue for light microscopy in order to
identify the area of interest.
Fibroblasts were collected and centrifuged at 775 xg for
5 min. The supernatant was discarded and pellet cells were
fixed with 2.5% glutaraldehyde in 0.1M sodium cacodylate
buffer (pH 7.2) supplemented with 1 mM calcium chloride for
2 h. Following rinsing in the same buffer, post-fixation was
performed using 1% osmium tetroxide for 1 h. After rinsing
twice in buffer, and distilled water and, 1% aqueous uranyl
acetate was added to the cells, for contrast enhancement during
1 h in the dark. After rinsing in distilled water, samples were
dehydrated in a graded acetone series (30–100%), impregnated
and embedded in Epoxy resin (Fluka Analytical).
Finally, for both preparations, ultrathin sections (70 nm)
were mounted on copper grids (300 mesh) and stained with lead
citrate 0.2%, for 7 min. Observations were carried out on a
FEI-Tecnai G2 Spirit Bio Twin at 100 kV and images were
acquired using the software AnalySIS 3.2.
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2.9. Statistical analysis
Data were analysed using GraphPad Prism version 5.00
software for Windows, San Diego, California, USA. Normality
tests were applied in order to assure the Gaussian distribution of
the results. Statistical analysis of the patient’s vs. controls’
results was assessed by a Student’s t-test (or nonparametric
Mann-Whitney test).
Statistical significance is represented as * for 0.050 ≥ p > 0.010,
** for 0.010 ≥ p > 0.001 and *** for p ≤ 0.001.
3. Results
3.1. Histochemistry and quadruple immunofluorescence
presented evidences for mitochondrial dysfunction in muscle
Histological and histochemical examination of
cryosectioned patient skeletal muscle revealed the presence of
approximately 10% RRF as a result of mitochondria
subsarcolemmal accumulation (Fig. 1A,B) and a significant
proportion (40%–50%) of COX-deficient fibres (Fig. 1C–E).
Assessment by quadruple immunofluorescence (Fig. 2A)
showed an equal down regulation (43%) of both CI and CIV
levels in individual fibres (Fig. 2B); the MRC profile (Fig. 2B)
was similar to the profiles previously reported for single, large-
scale deletion [33].
3.2. Genetic investigation revealed the presence of the
“common deletion” and a novel mt-tRNASer(UCN) variant at
high levels in muscle
The entire mitochondrial genome analysis by NGS
revealed previously reported polymorphisms and a novel
heteroplasmic variant in the mt-tRNASer(UCN) (m. 7486G>A,
ClinVar accession number: SCV000492500) (Supplementary
material – Table S1) in the patient’s muscle homogenate,
fibroblasts and lymphocytes. Besides, a heteroplasmic single,
large-scale deletion was detected in muscle homogenate and
fibroblasts of patient, but not in blood, with the sequence
breakpoints determined as 8482–13447, corresponding to the
“common deletion”.
The previous analysis determined that the patient belongs to
the haplogroup H+16311.
Heteroplasmy quantification of the mt-tRNASer(UCN) variant
(m.7486G>A) was obtained by pyrosequencing in fibroblasts
(~10%) and muscle homogenate (~50%).
The sequence variation was present at residue 32 in the
anticodon loop of mt-tRNASer(UCN) affecting a 3-methylcytidine
post-transcriptional position (Fig. 3A). The evolutionary
conservation showed that cytosine is conserved throughout
evolution (Fig. 3B). Moreover, the same alteration was not
detected in the DNA samples of 200 controls screened by
Sanger sequencing (data not shown).
Long-range PCR for ~10 kb amplification presented a
product size band with ~10 kb (wild type) and also ~5 kb,
confirming the presence of the single, large-scale deletion
(Fig. 3D), which is in agreement with the deletion size detected
by NGS.
Single muscle fibre analysis revealed significantly
higher levels of the heteroplasmic variant m.7486G>A
(***p < 0.0001) in COX-deficient fibres (92.24 ± 0.58%,
n = 29), compared to COX-positive fibres (14.96 ± 2.98%,
n = 26) (Fig. 3C). Also, the common deletion load showed
significantly higher levels (***p < 0.0001) in COX-deficient
Fig. 1. Histopathological features associated with mtDNA disease in patient’s skeletal muscle. (A) H&E staining showing general muscle morphology; (B) modified
Gomori trichrome staining highlighting muscle RRF; (C) SDH staining, which reveals subsarcolemmal accumulation of mitochondrial activity; (D) COX-deficient
fibres and COX-positive fibres; (E) sequential COX/SDH histochemistry emphasising individual COX-deficient fibres which retain SDH activity. Scale bar: 100 µm.
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fibres (89.58 ± 2, n = 27) and the absence of deletion in most of
COX-positive muscle fibres (n = 17), (Fig. 3E). Accordingly,
muscle homogenate presented 57% to 61% of deletion in the
three independent experiments performed.
3.3. Assembly of MRC complexes was impaired
A statistically significant reduction in the amount of fully-
assembled MRC complexes containing mtDNA-encoded
proteins was observed in the patient’s fibroblasts compared to
controls (Fig. 4A), suggesting a mitochondrial translation
defect. The results are similar for the four complexes with
mitochondrial subunits: CI (Fig. 4B, *p = 0.0162), CIII
(Fig. 4C, *p = 0.0127), CIV (Fig. 4D, *p = 0.0357) and CV
(Fig. 4E, *p = 0.0216).
3.4. Mitochondrial dysfunction detected in patient’s cells:
bioenergetics impairment, membrane depolarization and
morphological changes
Assessment of MRC enzymatic activity (Supplementary
material – Table S4) in muscle homogenate revealed a reduction
in CIV activity (44.8% of controls). Also, CV activity was
diminished in muscle and skin fibroblasts (69% and 66% of the
controls’ mean, respectively).
The OCR results showed a significant reduction in
mitochondrial respiration of the patient’s cells compared
to controls (Fig. 5A–F); there were evident differences
in basal respiration (***p = 0.0008), maximal respiration
(***p = 0.0008) and ATP production (***p < 0.0001).
Moreover, the addition of the uncoupler FCCP in cells pre-
exposed to oligomycin (to inhibit CV) caused a rise in
rhodamine 123 fluorescence that was significantly lower in the
patient’s cells than in controls’ cells (**p = 0.0084) (Fig. 5G),
suggesting mitochondrial membrane depolarization in patient’s
fibroblasts.
Remarkable morphological and ultrastructural differences
were observed between control (Fig. 6A) and patient (Fig. 6B)
skin fibroblasts, namely the presence of large multilamellar
bodies (MLB) (Fig. 6B). Mitochondrial hyperproliferation,
enlarged mitochondria and mitochondria presenting structural
alterations of cristae such as paracrystalline inclusions and
concentric “onion-shaped” cristae, were observed in patient’s
muscle (Fig. 6C–E).
4. Discussion
In the present report, we describe a patient with histological
and histochemical changes in muscle that were indicative of
OXPHOS dysfunction and mitochondrial disease. Both
immunofluorescence and MRC evaluation revealed decreased
levels and activity of multiple complexes in muscle sections
and homogenate, respectively, likely due to defective
mitochondrial translation. Deep genetic investigation allowed
the identification of the “common deletion” in muscle and
fibroblasts, and a novel mt-tRNASer(UCN) variation (m.7486G>A)
in muscle, fibroblasts and blood. For single-fibre studies, we
have used the same muscle fibres to quantify the levels of the
mtDNA deletion and the tRNA variant. Both presented high
levels within the isolated COX-deficient fibres and low levels
Fig. 2. Mitochondrial respiratory chain profile in patient’s biopsy. (A) Representative image of quadruple immunofluorescence (laminin – white (405 nm), NDUFB8
– purple (647 nm), COX-I – green (488 nm) and porin – red (546 nm)) performed in patient’s muscle section. (B) Mitochondrial respiratory chain profile showing
complex I, complex IV and porin levels in patient (n = 1022 fibres). Each dot represents an individual muscle fibre colour coded according to its mitochondrial mass
(very low: blue, low: light blue, normal: light orange, high: orange and very high: red). Thin black dashed lines indicate the SD limits for the classification of fibres,
lines next to x and y axis indicate the levels of NDUFB8 and COX-I respectively (beige: normal, light beige: intermediate(+), light blue: intermediate(−) and blue:
negative), bold dashed lines indicate the mean expression level of normal fibres.
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within COX-positive fibres. Consequently, it was not possible to
clarify the segregation of the tRNA variant alone, within the
COX-deficient fibres, because the biochemical segregation was
similar for both alterations. The percentage of deleted
molecules is probably enough to cause a clinical phenotype,
while the presence of a novel heteroplasmic variant in the
anticodon loop of the mt-tRNASer(UCN) was also relevant.
There are numerous examples of disease-causing mutations
in mt-tRNA genes and more than 20 variants, in 13 different
mt-tRNA genes, have been reported in association with CPEO
and/or myopathy [48]. Three of these have been reported in the
MT-TS1 gene (encoding mt-tRNASer(UCN)): m.7506G>A [49],
m.7451A>T [50] and m.7458G>A [51] have all been associated
with PEO. Nevertheless, the interpretation of pathogenicity for
mtDNA variants is complex and challenging. The pathogenic
variants in mt-tRNA genes may impair transcription
termination and tRNA maturation, reduce the aminoacylation,
abolish post-transcriptional modification of tRNA, decrease the
binding to translation factors or the mitoribosome, alter the
structure, perturb the stability, and disturb codon reading,
ultimately leading to loss of function [52,53]. The novel
variation m.7486G>A affects a highly conserved nucleotide
and alters the first base of the anticodon loop adjacent to the
anticodon stem (position 32 of mt-tRNASer(UCN)), disturbing a
3-methylcytidine (m3C) post-transcriptional modification
position [53–57]. Little is known about the function of this type
of modification, although a role in accurate codon recognition
and translation efficiency has been suggested [58,59]. Thus, the
m.7486G>A variation could affect the conformation of the
anticodon loop by creating a U32 pair with A38, that may
disturb the interaction with mitoribosome, thus reducing the
contact time for codon recognition. Similar defects in the
Fig. 3. Genetic investigation of the “common deletion” and the novel mt-tRNASer(UCN) variant. (A) Evolutionary conservation of m.7486G>A change in
mt-tRNASer(UCN) in different species. (B) Proposed secondary structure of mt-tRNASer(UCN). The gene is encoded in the light strand and thus the base change at position
7486 is shown as C to T. (C) Single-fibre analysis by pyrosequencing of the m.7486G>A mutation in individual COX-deficient and COX-positive muscle fibres,
showing a clear segregation of high mutation load with the biochemical defect. Mann-Whitney test, ***p < 0.0001. (D) Long-range PCR for detection of the
“common deletion”, amplifying approximately 10 kb of the mtDNA, producing a product size of approximately 5 kb. (E) Single fibre study for the presence of the
“common deletion” in individual COX-deficient and COX-positive muscle fibres after Real-time PCR analysis, showing a clear segregation of high mutant load with
the biochemical defect. Mann-Whitney test, ***p < 0.0001.
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conformation of the anticodon loop were suggested for
the m.7480T>C variation, reported as pathogenic and causing
mitochondrial myopathy, located in the anticodon loop of
mt-tRNASer(UCN) at position 38 (opposite to 32) [60]. The novel
variation herein reported was identified (about 90%) in COX-
deficient fibres of the affected tissue (muscle), segregating with
the biochemical phenotype but maintaining the mt-tRNASer(UCN)
steady-state levels (Supplementary material – Figure S1).
Accordingly, there is a possibility that the novel sequence
variant might compromise mt-tRNASer(UCN) anticodon function
by disrupting the correct binding of mitoribosome and/or the
recognition of the amino acid sequence, leading to
consequences in mitochondrial translational accuracy, without
any effect on mt-tRNASer(UCN) stability.
According to the scoring criteria [61] for characterisation of
the pathogenicity for the novel m.7486G>A variant, the score
totals 11 points, out of 20, as follows: (1) the variant was
heteroplasmic in different tissues (2 points); (2) the base is
conserved throughout evolution (2 points); (3) there was a
strong histochemical evidence of mitochondrial disease (2
points); (4) biochemical defects were detected in complexes I,
III or IV (2 points); and (5) the variant segregated with the
biochemical phenotype (3 points). Some of these criteria were
certainly influenced by the presence of the “common deletion”.
However, the specific criterion for the segregation with the
biochemical defect suggested that the sequence variation is
“probably pathogenic”.
The defective mitochondrial translation is predicted to be the
primary consequence of mutations affecting mt-tRNA genes,
leading to OXPHOS deficiency. The “common deletion” would
be expected to have a similar detrimental effect on translation of
all subunits encoded by mitochondrial genome. Therefore, the
most likely genetic cause of CPEO in this patient is the “common
deletion”, even though the m.7486G>A sequence variation holds
a huge pathogenic potential associated to the disease.
Since the first report [22], the consequences of the “common
deletion” have been characterized [3,5,26–30], namely the
decrease in MRC complexes activity [3,5,27,29], mitochondrial
protein synthesis [28], mitochondrial membrane potential and
ATP synthesis [30]. In fact, functional evidences were gathered,
demonstrating the inability to produce mtDNA-encoded
proteins, leading to incomplete fully assembled OXPHOS
complexes and resulting in electron transport deficiency,
inefficient respiration and depolarization of mitochondrial
membrane, confirming previous studies.
Concerning ultrastructural alterations, the most relevant
finding in fibroblasts was the presence of MLB, which could be
interpreted as an expression of cellular damage, suggesting
alterations of autophagy, similarly to the hypothesis proposed
by Signorini and colleagues in skin fibroblasts of patients
affected with Rett Syndrome [31] and Thomas and co-workers
in fibroblasts of patients presenting Spinocerebellar Ataxia,
autosomal recessive 20 [62]. The accumulation of abnormal
mitochondria in the patient’s skeletal muscle, presenting
Fig. 4. (A) Blue-native PAGE followed by immunoblot with antibodies directed against specific individual subunits, in order to quantify the fully assembled
OXPHOS complexes. Complex II was used as loading control. (B) Relative fully assembled complex I level, *p = 0.0162; (C) Relative fully assembled complex III
level, *p = 0.0127; (D) Relative fully assembled complex IV level, *p = 0.0357; (E) Relative fully assembled complex V level, *p = 0.0226. The analysis was
performed using Mann-Whitney test. Results are representative of the mean ± SEM based on at least three independent experiments in duplicate. C – Complex.
ARTICLE IN PRESS
Please cite this article in press as: Mafalda Bacalhau, et al., Disclosing the functional changes of two genetic alterations in a patient with Chronic Progressive External Ophthalmoplegia:
Report of the novel mtDNA m.7486G>A variant, Neuromuscular Disorders (2017), doi: 10.1016/j.nmd.2017.11.006
7M. Bacalhau et al. /Neuromuscular Disorders ■■ (2017) ■■–■■
paracrystalline inclusions and concentric cristae, reinforces the
mitochondrial dysfunction observed in this tissue, as previously
described for myopathy caused by single, large-scale mtDNA
deletion or mt-tRNA mutations [63]. These results strongly
suggest that defects in the proteolytic systems, namely
mitophagy, responsible for the elimination of damaged or
dysfunctional mitochondria, can be implicated in the disease.
In conclusion, we describe a patient presenting with CPEO
who harbours two genetic alterations contributing to the clinical
phenotype: a single, large-scale mtDNA deletion and a novel
mt-tRNA sequence variant. Both alterations were detected by
NGS. However, due to technical limitations, more specific
analyses were performed in order to confirm and quantify the
level of heteroplasmy of the mtDNA deletion and the tRNA
variant. Since both alterations show high levels in muscle,
appear to segregate with the biochemical defect and may
promote inefficient mitochondrial translation, it is difficult to
assign the isolated impact of the novel mt-tRNA sequence
variation, thus demonstrating the inherent difficulties in
proving the pathogenicity of novel or rare mtDNA variants.
The “common deletion” is the most likely genetic cause.
However, the potential pathogenic effect of the novel
mt-tRNASer(UCN) sequence variation cannot be ignored, and it
may be valuable in evaluating further cases. Similar patients
(i.e. presenting with two mtDNA genetic defects) are reported
in the literature; one patient presented with myopathy and
autoimmune polyendocrinopathy due to a single mtDNA
deletion co-existing with the pathogenic m.3243A>G variant
[64]; another patient presented with limb-girdle myopathy
associated with two, heteroplasmic mtDNA sequence variants
[65]; together with the case we report here, these reinforce the
idea that multiple mtDNA variants may act synergistically to
influence clinical phenotype.
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